Compare LRHC & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LRHC | SXTP |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9M | 2.9M |
| IPO Year | 2023 | 2023 |
| Metric | LRHC | SXTP |
|---|---|---|
| Price | $0.69 | $0.51 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $4.40 |
| AVG Volume (30 Days) | ★ 294.0K | 193.3K |
| Earning Date | 11-19-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $78,660,186.00 | $1,364,945.00 |
| Revenue This Year | N/A | $146.28 |
| Revenue Next Year | N/A | $24.61 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 24.52 | ★ 202.10 |
| 52 Week Low | $0.63 | $0.45 |
| 52 Week High | $95.20 | $8.00 |
| Indicator | LRHC | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 20.85 | 18.54 |
| Support Level | $0.63 | $0.45 |
| Resistance Level | $0.75 | $0.57 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 4.36 | 14.44 |
La Rosa Holdings Corp operates in the U.S. residential real estate market. It is a holding company for agent-centric, technology-integrated, cloud-based, multi-service real estate companies. The company's business is organized based on the services it provides internally to the agents and to the public, which are residential and commercial real estate brokerage, franchising, real estate brokerage education and coaching, and property management. The company has six reportable segments, namely: Real Estate Brokerage Services (Residential), Franchising Services, Coaching Services, Property Management, Real Estate Brokerage Services (Commercial), and Title Settlement and Insurance. It derives maximum revenue from the Real Estate Brokerage Services (Residential) segment.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline products under development cover development programs for COVID-19, fungal, tick-borne, and other viral diseases.